quinazolines has been researched along with niclosamide in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, ZG; Curran, WJ; Deng, X; Hu, Z; Khuri, FR; Li, R; Owonikoko, TK; Ramalingam, SS; Sica, GL; Sun, SY | 1 |
| Chen, ZG; Curran, WJ; Deng, X; Hu, Z; Khuri, FR; Li, R; Shin, DM; Sica, GL; You, S | 1 |
2 other study(ies) available for quinazolines and niclosamide
| Article | Year |
|---|---|
Niclosamide overcomes acquired resistance to erlotinib through suppression of STAT3 in non-small cell lung cancer.
Topics: Apoptosis; bcl-X Protein; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Humans; Mutation; Niclosamide; Phosphorylation; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Signal Transduction; STAT3 Transcription Factor; Xenograft Model Antitumor Assays | 2013 |
Inhibition of STAT3 by niclosamide synergizes with erlotinib against head and neck cancer.
Topics: Antineoplastic Agents; Base Sequence; Cell Line, Tumor; DNA Primers; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Head and Neck Neoplasms; Humans; Niclosamide; Phosphorylation; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; STAT3 Transcription Factor | 2013 |